

MANAGEMENT DECLARATION

Declaration in accordance with Section § 315d and § 289f HGB of the German Commercial Code (Handelsgesetzbuch – HGB)

CONSTITUTION OF THE COMPANY

Biotest AG is a joint stock company under German law (*Aktiengesellschaft* – AG). Its management, decision-making and control mechanisms are based on the Company's Articles of Association together with the relevant statutory provisions. The current version of these is available for download on the Company's website at www.biotest.com.

CORPORATE GOVERNANCE

Biotest AG employs a two-tier management system in accordance with statutory requirements. The Board of Management is responsible for managing the Company and the Supervisory Board for the monitoring function. The two bodies are strictly separate and distinct in terms of membership and responsibilities.

The Biotest Group is managed and monitored in accordance with high, generally accepted standards. The Company's management principles are firmly established in all its segments and set forth the framework for strategic decisions and business policies.

The Board of Management and Supervisory Board closely follow ongoing discussions regarding corporate governance and systematically adopt *best practices*. Our understanding of responsible corporate governance is based on the following principles:

- The Board of Management and the Supervisory Board work together in confidence for the benefit of the Company. The Supervisory Board exercises its monitoring function efficiently and independently.
- The Company is managed with the interests of the shareholders in mind at all times.
- A responsible, appropriate and effective internal control and risk management system is practiced.
- Observing and complying with legal, supervisory and regulatory requirements as well as internal guidelines is of highest priority.
- Timely and transparent communication, both internal and external, is assured.

The basis of cooperation is set forth in working rules. These are handed out to each employee at the start of employment.

Management by the Board of Management

The Board of Management manages the Company on its own responsibility. It is bound to serve the Company's interests and to increase its value with a view to sustainable performance.

It develops the Company's strategies in coordination with the Supervisory Board and ensures their implementation.

The Board of Management manages the Company in accordance with Rules of Procedure, the law, the Articles of Association and the respective service contracts of its members. The Board of

Management works together with other corporate bodies and employee representatives on the basis of mutual trust for the good of the Company.

According to the Articles of Association, the Board of Management may consist of one or more members.

Until August 31, 2024, the Board consisted of three members, Mr Peter Janssen, Ms Ainhoa Mendizabal Zubiaga and Dr Jörg Schüttrumpf. Dr Jörg Schüttrumpf left the Company at his own request on August 31, 2024 to take up a position at Grifols, S.A. On September 10, 2024, Ms Ainhoa Mendizabal Zubiaga left the Company for personal reasons.

By resolution dated September 15, 2024, the Supervisory Board appointed Mr Martin Möller as a member of the Board of Management of Biotest AG. The appointment was made for a fixed term until March 15, 2025. He is responsible for financial affairs (Chief Financial Officer, CFO). Peter Janssen has been Chairman of the Board of Management (Chief Executive Officer, CEO) since January 1, 2024.

Currently, the Board of Management consists of two members: Mr Peter Janssen (CEO) and Mr Martin Möller (CFO).

All members of the Board of Management were appointed by the Supervisory Board.

The Company is legally represented by two Board of Management members or by one Board of Management member and an authorised officer (*Prokurist*). The Rules of Procedure of the Board of Management provide for the detailed structure of the Board's work. These specifically include:

- the schedule of responsibilities which determines which business areas are to be managed by the Board of Management member under his/her own responsibility,
- decisions to be made by the Board of Management as a whole,
- the special duties of the Chairman of the Board of Management,
- transactions requiring Supervisory Board approval,
- regular, timely and comprehensive briefing of the Supervisory Board,
- rules regarding meetings and resolutions.

Monitoring and advising by the Supervisory Board

The Supervisory Board monitors the Board of Management and advises it regularly. The composition of the Supervisory Board is in accordance with the German One-Third Participation Act (*Drittelbeteiligungsgesetz*) and is comprised of six members; four of the members are elected by the Annual Shareholders' Meeting and two by employees.

In 2024, the composition of the Supervisory Board of Biotest AG changed. Ms Uta Kemmerich-Keil resigned from office as a member of the Supervisory Board and as Chairwoman of the Audit Committee with effect as of September 30, 2024. On November 28, 2024, Prof Dr Gernot Hebestreit was appointed by the court as a member of the Supervisory Board until the end of the next Annual General Meeting, but no longer than December 31, 2025. On December 9, 2024, the Supervisory Board elected Prof Dr Gernot Hebestreit as Chairman of the Audit Committee.

The Supervisory Board performs in full all tasks with which it is entrusted under the terms of statutory provisions, the Articles of Association and the German Corporate Governance Code (GCGC).

All duties and powers of the committees are laid down in the Supervisory Board's Rules of

Procedure. Further, the Company adopted a qualification profile for the members of the Supervisory Board. The Rules of Procedure for the Supervisory Board (available on the Company's website (www.biotest.com)) also include most of the GCGC requirements, e.g. in respect of the professional competence of the Supervisory Board members, restrictions imposed on Supervisory Board mandates in other listed companies.

Other rules relate to:

- the election and duties of the Supervisory Board Chairman and Deputy Chairman,
- the convening of meetings,
- decision-making during meetings and outside meetings in writing or by telephone,
- the obligation to maintain confidentiality and mandatory disclosure of conflicts of interest.

The Supervisory Board has set up two committees in order to increase its efficiency. The duties of the committees are described in the Articles of Association and the Rules of Procedure of the Supervisory Board, which can be found on the Company's website (www.biotest.com). The two committees are composed as follows:

	Duties	Members
Personnel and Compensation Committee	Board of Management appointments and remuneration Preparation of recommendations and motions with regard to new contracts for the Supervisory Board as a whole	Dr Bernhard Ehmer (Chairman) Raimon Grifols Roura Jürgen Heilmann
Audit Committee	Monitoring the accounting process, the effectiveness of the internal control system, the risk management system and the internal audit system, as well as the audit of the financial statements, in particular the selection and independence of the auditor and the auditor services provided by the auditor	Uta Kemmerich-Keil (Chairwoman, until September 30, 2024)) Prof Dr Gernot Hebestreit (Chairman, from December 9, 2024) David Bell Dr Bernhard Ehmer Dirk Schuck

In the second quarter 2024, the Supervisory Board last reviewed the efficiency of its work with the help of an experienced executive consulting company. Based on a structured questionnaire the consultants have investigated and compared the working method, style and efficiency of the Supervisory Board by conducting individual interviews with all members of the Supervisory Board and the Board of Management. The results outlined in a report have been discussed and evaluated in a Supervisory Board meeting. As consequence, several measures had been taken.

Reportable transactions with financial instruments/share transactions by the Board of Management and Supervisory Board

Members of the Board of Management and the Supervisory Board are subject to a reporting obligation in accordance with Art. 19 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 2014 on market abuse (Market Abuse Regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC to disclose proprietary transactions in shares or debt instruments of Biotest AG or related derivatives or other related financial instruments if the total amount of the transactions carried out by the member or related parties within a calendar year reaches or exceeds the sum of EUR 20,000.00. The transactions reported to Biotest AG are being published duly and are available on the Company's website at: https://www.biotest.com/de/de/investor_relations/news_und_publicationen_/eigengeschaefte-von-fuehrungsk.cfm. In the 2024 financial year no reportable transactions were reported to the Company.

Specification to promote the participation of women in executive positions pursuant to Sections 76 Paragraph 4 and 111 Paragraph 5 of the German Stock Corporation Act (Aktiengesetz - AktG)

Promotion of women in executive positions

An adequate representation of women in the workforce and, in particular, among the executives, provides an important added value to the Biotest Group. The "German Act on the Equal Participation of Women and Men in Executive Positions in the Private Economy and the Public Service", as amended and supplemented by the "Act to Supplement and Amend the Regulations for the Equal Participation of Women in Leadership Positions in the Private Sector and in the Public Sector" (so-called "Second Leadership Positions Act"), which came into force on 12 August 2021, provides that companies such as Biotest AG, which are listed on the stock exchange and are subject to co-determination in accordance with the One-Third Participation Act (*Drittelbeteiligungsgesetz*), must set their own targets for gender participation for the Supervisory Board, the Board of Management and subordinate management levels.

In accordance with this, Biotest AG set target figures for the participation of women in executive positions, which are to be met by June 30, 2026. The target figure for the first two management levels was set at 35% until June 30, 2026. The Management Board has decided to leave the target figure at 35% and will critically review the target figure in the future based on developments.

Women on the Supervisory Board

The Supervisory Board of Biotest AG is composed of six members, four of whom represent the shareholders, and two of whom represent the employees. Until September 30, 2024, one woman was elected to the Supervisory Board as representative of the shareholders. Since November 28, 2024, all representatives of the shareholders have been male. Both of the representatives of the employees are male. The target variable has fallen below the minimum target of 30 % women.

Women on the Board of Management

Until September 10, 2024, Ms Ainhua Mendizabal was a member of the Board of Management of the Company and was responsible for Finance, Controlling, Investor Relations and Insurance. Until September 10, 2024, the target of 33 % for women on the Board of Management was met. Since

then, all members of the Board of Management are male and the target is thus not met.

The Supervisory Board does not consider a change in the composition of the Board of Management or an increase of the number of members solely for the purpose of increasing the proportion of women to be appropriate. Due to the urgency, the professional qualifications and experience were the deciding factors for the selection of Mr Martin Möller as an additional member of the Management Board. By June 30, 2026, the proportion of women on the Board of Management is to increase again to at least 33%.

Women at the first and second management level

The Board of Management of Biotest AG has set a target figure of 30 % for the participation of women at the first management level by January 1, 2025 and has exceeded this target by December 31, 2024 with 46.2 %. The target figure for the second management level was set at 30 % by January 1, 2025 and as of December 31, 2024, the proportion of women at that management level was 28.0 %. The proportion of women at Biotest group level (1,397 female employees) was 52.4 % as of December 31, 2024.

Succession planning for the Board of Management

Long-term succession planning with regard to appointments to the Board of Management is secured through regular dialogue amongst the Chairmen of the Board of Management and the Supervisory Board and regular discussion of the topic by the Supervisory Board. This includes the discussion of terms of the service contracts of current Board of Management members and possible extensions as well as considering possible successors. In succession planning for the Board of Management, the Supervisory Board ensures, among other things, that the age limit of 63 years is observed.

Diversity concept for the composition of the Board of Management and the Supervisory Board

Beyond the diversity objectives for the composition of the Board of Management and the Supervisory Board set out in this Management Declaration as well as the particular objectives as set out in the qualification profile for the composition of the Supervisory Board Biotest AG has not yet established a diversity concept within the meaning of Section 289f para. 2 No. 6 HGB. In the past, the Supervisory Board has always taken into account, even in the absence of an abstract diversity concept, that its composition and that of the Board of Management meet the specific needs of the Company.

Qualification profile and targets for the composition of the supervisory board

Requirements on the Composition of the Supervisory Board

Qualification profile

The Supervisory Board shall have the competencies which are considered essential for the activities and business of the Biotest Group. This includes in particular extensive and in-depth knowledge and experience in

- the management of a mid-size, internationally operating company;
- the healthcare/life science/pharma sector;
- the areas of research & development (especially also in clinical development and drug approval) production, marketing, sales;
- digitisation and innovation management;

- the main markets in which Biotest operates;
- business administration;
- the area of governance/compliance/risk management;
- the sustainability sector.

In addition, with regard to the requirements of Section 100 para. 5 of the German Stock Corporation Act, for members of the Supervisory Board appointed after 1 July 2021, at least one member of the Supervisory Board must have expertise in the field of accounting and at least one other member of the Supervisory Board must have expertise in the field of auditing, and the Supervisory Board members in general must be familiar with the pharmaceutical industry. Pursuant to Section 107 para. 4 sent. 3 of the German Stock Corporation Act, the requirements of Section 100 para. 5 of the German Stock Corporation Act apply accordingly to the Audit Committee.

The expertise in the field of accounting shall consist of special knowledge and experience in the application of accounting principles and internal control and risk management systems, and the expertise in the field of auditing shall consist of special knowledge and experience in the auditing of financial statements. Accounting and auditing also include sustainability reporting and its audit and assurance. The chairman of the Audit Committee shall have appropriate expertise in at least one of the two areas.

As the communication at the meetings and the documents for their preparation are in English, each member of the Supervisory Board should have a good knowledge of the English language.

Independence and Potential Conflicts of Interests

The Supervisory Board shall include what its shareholder representatives consider to be an appropriate number of independent members representing shareholders; thereby taking into account the shareholder structure.

A member of the Supervisory Board shall be deemed independent within the meaning of this recommendation if, in accordance with recommendation C.7 of the GCGC, he or she is independent of the Company and its Board of Management and, in accordance with recommendation C.9 of the GCGC, independent of a controlling shareholder. It is being understood that an employment relationship within the Biotest Group or membership or activity in an employee representative body does not affect the independence of an employee representative.

If the Company has a controlling shareholder, and the Supervisory Board comprises more than six members, at least two shareholder representatives shall be independent from the controlling shareholder. If the Supervisory Board comprises six members or less, at least one shareholder representative shall be independent from the controlling shareholder.

The Chair of the Supervisory Board, the Chair of the Audit Committee, as well as the Chair of the committee that addresses Board of Management remuneration, shall be independent from the Company and the Board of Management. The Chair of the Audit Committee shall also be independent from the controlling shareholder.

Supervisory Board members shall not be members of governing bodies of, or exercise advisory functions at, significant competitors of the Company and shall not hold any personal relationships with a significant competitor.

No more than two former members of the Board of Management shall be members of the Supervisory Board.

Diversity

In favour of diversity, the Supervisory Board shall take into account different professional and international experiences, in particular also an appropriate participation of women and men for its composition. The Supervisory Board shall be comprised of at least 30 % women and at least 30 % men. Shareholder and employee representatives bear joint responsibility for fulfilling these participation quotas.

Industry and international Expertise

At least one shareholder representative shall have many years of international professional experience. It would be desirable if at least one member of the Supervisory Board has knowledge of the international pharmaceutical market, ideally in the Biotest indication areas of haemophilia, immunology and intensive care.

Requirements for Individual Members of the Supervisory Board

General Requirements Profile

Supervisory Board members shall have entrepreneurial or operational experience and general knowledge of the pharmaceutical industry, in particular in the area of plasma protein products and biotherapeutic drugs manufacturing. Based on their knowledge, skills and professional experience, the members of the Supervisory Board should be able to perform their duties in an internationally operating company.

With regard to election proposals to the Annual Shareholders' Meeting, particular attention shall be paid to the personality, integrity, motivation and independence of the candidates. Supervisory Board members shall comply with the limitation of supervisory board mandates as set out in the Rules of Procedure for the Supervisory Board and comply with the recommended limitation of supervisory board mandates in accordance with recommendation C.4 of the GCGC.

Time Availability

Each member of the Supervisory Board ensures that he/she can make available the expected time required for the duly exercise of his/her mandate. The following must be taken into account:

- At least five ordinary Supervisory Board meetings are held each year, each of which requires an appropriate period of time for preparation.
- Sufficient time shall be reserved for the examination of the annual and consolidated financial statements.
- Membership in one or more committees requires additional time.
- Additional extraordinary Supervisory Board or committee meetings may be necessary to deal with special situations or special topics.

Age Limit

The members of the Supervisory Board shall not be older than 72 years at the time of their election.

Standard term of Supervisory Board mandate

Members of the Supervisory Board shall generally not be on the Supervisory Board for more than 15 years or three terms of office.

Election proposals for the Supervisory Board to the Annual Shareholders' Meeting shall take these targets into account and at the same time aim to reflect the qualification profile for the full Supervisory Board.

Status of implementation

In its current composition, the Supervisory Board fulfils almost all requirements of the qualification profile for the collegiate body and the individual members, in particular the requirements in relation to professional and personal qualifications and with regard to the knowledge, skills and experience essential for Biotest AG, as well as internationality.

The Supervisory Board takes into account the objectives for the composition and the requirements set out in the qualification profile as part of the selection process and nomination of candidates for the Supervisory Board. In preparing the election proposals for the four shareholder representatives to be elected by the Annual Shareholders' Meeting 2022, the Supervisory Board nominated a woman for election. She resigned from her position for personal reasons. No suitable woman could be found at short notice to succeed her. Female candidates were also nominated for the election of employee representatives, who were not elected as employee representatives.

Taking into account the ownership structure, the Supervisory Board on the shareholder side includes two independent members and what they consider to be an appropriate number of independent members. Dr. Bernhard Ehmer and Prof Dr Gernot Hebestreit are independent of the Company and its Board of Management and independent of the controlling shareholder. This also applied to the resigned Ms Uta Kemmerich-Keil.

Prof. Dr. Hebestreit has knowledge in the field of accounting and auditing due to his work in the field of auditing and business consulting and his membership of the audit committees of several companies. Ms Uta Kemmerich-Keil also had expertise in the field of auditing. Dr. Bernhard Ehmer has knowledge in the field of accounting principles due to his many years of experience in the management bodies of several internationally operating companies.

The implementation status of the competence profile as of December 31, 2024 is disclosed below in the form of a qualification matrix.

Qualification Matrix		Shareholder representatives					Employee representatives	
		Uta Kemmerich-Keil	David Bell	Dr. Bernhard Ehmer	Raimon Grifols Roura	Prof. Dr. Gernot Hebestreit	Dirk Schuck	Jürgen Heilmann
Length of membership	Member since	5 May 2022	6 June 2022	5 May 2022	9 May 2023	28.11.2024	5 May 2022	21. September 2011
Personal aptitude	Independence	✓		✓		✓		
	No Overboarding	✓	✓	✓	✓	✓	✓	✓
Diversity	Date of birth	27.12.1966	15.05.1954	03.02.1955	15.03.1964	22.04.1963	30.08.1978	09.01.1962
	Gender	Female	Male	Male	Male	Male	Male	Male
	Nationality	German	British / USA	German	Spanish	German	German	German
	Management of a mid-size, internationally operating company	✓	✓	✓	✓	✓		
	Healthcare/ life science/ pharma sector	✓	✓	✓	✓		✓	✓

Professional aptitude	Research & development/ production / marketing / sales	✓	✓	✓	✓	✓		
	Digitisation and innovation management	✓	✓	✓	✓		✓	
	Main markets in which Biotest operates		✓	✓	✓		✓	✓
	Business administration	✓		✓	✓	✓	✓	✓
	Area of governance/co compliance/risk management	✓	✓	✓	✓	✓	✓	
	Sustainability		✓	✓	✓	✓	✓	✓
	Accounting principles	✓		✓	✓	✓	✓	✓
	Auditing	✓				✓	✓	✓

According to the Code.

According to Section 100 para. 5 Stock Corporation Act and recommendation D.3 of the Code

- ✓ Criterion met, based on a self-assessment by the Supervisory Board. A dot means at least "good knowledge" and thus the ability to understand the relevant issues well and make informed decisions on the basis of existing qualifications, the knowledge and experience acquired in the course of work as a member of the Supervisory Board (for example, many years of service on the Audit Committee) or the training measures regularly attended by all members of the Supervisory Board.

Collaboration between the Board of Management and the Supervisory Board

The Board of Management informs the Supervisory Board regularly, promptly and comprehensively of all issues of strategy, planning, business development, the risk situation, risk management and compliance that are relevant to the Company.

It provides a monthly report on the Company's business and earnings position, including plan and target variances together with an explanation. Certain business transactions, such as the acquisition and disposal of participations in other companies, fundamental changes in the corporate organisation or business strategy and capital increases or decreases require the prior approval of the Supervisory Board.

Supervisory Board members are provided with all decision-relevant documents, including the annual financial statements, consolidated financial statements, the non-financial statement, the auditor's reports and the summary of the internal audit reports in a timely manner before each meeting.

Members of the Board of Management attend meetings of the Supervisory Board in an advisory capacity, unless, in individual instances, the Supervisory Board or its Chairman decides otherwise.

Remuneration system and remuneration of the members of the Board of Management

The applicable remuneration system for the members of the Board of Management pursuant to Section 87a para. 1 and para. 2 sent. 1 of the German Stock Corporation Act, which was approved by the Annual Shareholders' Meeting on May, 11 2021, as well as the resolution adopted by the Annual Shareholders' Meeting on May, 11 2021 pursuant to Section 113 para. 3 German Stock Corporation Act on the remuneration system of the members of the Supervisory Board are publicly

available on the website of Biotest AG (at https://www.biotest.com/de/de/investor_relations.cfm#). In addition, the remuneration report and the auditor's report pursuant to Section 162 German Stock Corporation Act are also made publicly available on the website of Biotest AG (at https://www.biotest.com/de/de/investor_relations.cfm).

MANAGEMENT AND CONTROL OF GROUP COMPANIES

The Group's affiliated companies are corporations that may differ in legal form depending on their domicile. The companies are managed by a Board of Management or a comparable institution. Shareholders' meetings set the guidelines for the respective company strategy and make key investment and business decisions.

In principle, Group management approval is required for all key business decisions at the affiliate level.

COMPLIANCE IN THE BIOTEST GROUP

Biotest defines compliance as a series of internal corporate policies and procedures that are undertaken by a company and that promote the prevention, detection, and resolution of conduct or practices that are illegal or that do not conform to the Company's ethical and business standards.

The rights and duties of individual employees in the Biotest Group are governed by Biotest's Code of Ethics and Business Conduct (Code of Conduct) that is published on the Biotest website and in the national compliance manuals and are comprehensively set out on the Intranet and regularly updated. The most essential content and messages of the Code of Conduct have been summarized in a leaflet which was distributed to all employees and relevant business partners in electronic and physical form.

To counteract the risk of compliance violations, the Biotest Group, in close cooperation with the Compliance, Legal and Information Technology departments, further expanded the international compliance system, taking into account country-specific features. Compliance processes were further developed in 2024, primarily by setting up an electronic whistle blower system, fine-tuning the compliance review process and online compliance training as well as, aligning Compliance policies and procedures, where appropriate, to those of Grifols.

The mandatory face-to-face training on the Biotest Compliance Code of Conduct for all new employees and those who have not been trained for three years, were changed to an online course or refresher course that will take place annually in the future. In addition to the online training on the Code of Conduct specifically tailored to Biotest, the Legal and Compliance departments have developed further training in the areas of antitrust law and data protection in cooperation with an external service provider in 2024. In addition, annual training courses on the policy for health care professionals were held in 2024, followed by an electronic test for the relevant departments..

Biotest AG is a member of the "Verein Arzneimittel und Kooperation im Gesundheitswesen e.V." (AKG = Pharmaceuticals and Cooperation in Healthcare Association) based in Berlin, Germany. This voluntary self-regulating organisation was established by German-based pharmaceutical companies to guard against competitive violations.

Biotest AG has established a compliance system that implements and specifies the requirements under the Code of Conduct for daily cooperation with business partners and in particular with health care professionals or health care organisations such as hospitals, doctors and other medical specialists (healthcare professionals). Its particular concern is to combat the risk of corruption in connection with pharmacotherapy. Transactions of Biotest AG with healthcare professionals that may involve compliance risks, such as training courses, expert meetings, lectures and application

observations financially supported by Biotest, are subject to the prior written approval of the Compliance Department.

Biotest has also implemented an electronic system to ensure that payments to healthcare professionals are made in accordance with compliance rules. This system is also used to archive all data that must be stored in connection with payments to healthcare professionals. In accordance with the Transparency Rule of the AKG (Section 28 of the AKG Code), Biotest publishes on its website all cash-equivalent benefits to healthcare professionals on an annual basis. Until the end of 2024, a whistleblower hotline was available at a law firm, which was replaced by an electronic whistleblower system at the turn of the year. The so-called Biotest SpeakUp Helpline now enables confidential and, if desired, completely anonymous reporting.

Biotest AG and its subsidiaries regularly exchange information on the implementation and adaptation of Biotest AG's compliance systems. Besides the Group wide Code of Ethics and Business Conduct, the revised national policies for healthcare professionals and other local regulations are successively published on the Biotest Group Intranet, making them transparent for all employees.

Biotest's international business also includes cooperation with sales partners in countries with particular corruption and money laundering risks. Therefore, all sales partners abroad are screened for suspicions of corruption, money laundering or other criminal offenses or unethical behaviour against social and environmental standards on the basis of a risk-based approach when the contract is established and continuously thereafter. Potential partners from high-risk countries or with a particular risk profile are examined particularly intensively. The countries Biotest operates in also include countries against which sanctions have been imposed. Biotest AG has observed and complied with these sanctions.

All distributors and agents confirm receipt of the current Code of Conduct on a regular basis and undertake to comply with its provisions. Distributors and agents regularly attend information events on compliance topics and the Code of Ethics and Conduct.

TRANSPARENCY AND FINANCIAL ACCOUNTING

The Biotest Group is committed to regular, open and timely communication with institutional investors and analysts, private shareholders, employees and other stakeholders.

Biotest AG regularly shares information with shareholders, all of whom are treated equally in terms of the information provided to them. All new developments are communicated without delay by means of press releases and ad hoc announcements, annual and interim financial reports, and presentations to analysts' and investors' conferences. The information, as well as the financial calendar and information on the Annual Shareholders' Meeting, can be viewed and downloaded from the Biotest website (www.biotest.com).

Information is also published with regard to directors' dealings and voting rights announcements, along with all information which must be published under corporate law.

The annual consolidated financial statements, the interim financial reports and the quarterly statements for the first three, six and nine months of each financial year are prepared by the Board of Management. These statements are prepared on the basis of the International Accounting Standards (IAS) adopted and published by the International Accounting Standards Board (IASB) or the International Financial Reporting Standards (IFRS) as applicable in the EU as well as the interpretations of the Standing Interpretations Committee (SIC) or the International Financial Reporting Interpretations Committee (IFRIC).

Biotest AG's single entity financial statements, on which dividend payments are based, are drawn

up in accordance with the provisions of the German Commercial Code.

ANNUAL SHAREHOLDERS' MEETING

The Annual Shareholders' Meeting is the Company's supreme governing body and is of central importance to the dialogue between shareholders and the Board of Management and Supervisory Board. By providing comprehensive information in advance of the Annual Shareholders' Meeting, Biotest AG ensures that shareholders are able to make full use of their rights.

The Annual Shareholders' Meeting passes its resolutions with a simple majority of votes cast and, in cases where a capital majority is required, with a simple majority of the share capital represented – unless stipulated otherwise by law or the Articles of Association.

The most important information and details about the Annual Shareholders' Meeting are published on the Biotest website (www.biotest.com). The report of the Board of Management and the accompanying presentation are also made available there in a timely manner.

DECLARATION OF COMPLIANCE

Declaration of the Board of Management and the Supervisory Board of Biotest AG on the recommendations of the German Corporate Governance Code in accordance with Section 161 of the German Stock Corporation Act (AktG)

Since the last Declaration of Compliance dated 15 March 2024, Biotest AG has complied with all recommendations of the German Corporate Governance Code (GCGC) in the version of 28 April 2022 with the following exceptions:

- Contrary to recommendation D.4 of the GCGC, the Supervisory Board of Biotest AG has not formed its own nomination committee, which is composed exclusively of shareholder representatives and nominates suitable candidates to the Supervisory Board for its proposals to the Annual General Meeting for the election of Supervisory Board members. The duties of the nomination committee are assumed by the Personnel and Compensation Committee.
- Biotest AG has not complied in part with recommendation D.10 of the GCGC. According to sentence 3 of recommendation D.10 of the GCGC, the Audit Committee should regularly consult with the auditor even without the Board of Management. From the perspective of the Supervisory Board and the Audit Committee, the participation of the Board of Management in Audit Committee meetings has always been required to date. The Audit Committee may meet and consult without the Board of Management or the auditor if the Supervisory Board or the Audit Committee deems this to be necessary.
- Contrary to recommendation G.3 of the GCGC, the Supervisory Board of Biotest AG has so far used the peer group of other companies to assess the appropriateness of the specific total remuneration of the members of the Board of Management, but has not disclosed it. The use of the peer group of other companies was explained in the Annual General Meeting 2024 by means of a horizontal and vertical comparison of the average and owed remuneration of the Board of Management and all employees of Biotest AG as well as the remuneration of currently serving and former members of the Board of Management.
- Biotest AG has not complied with recommendation G.10 of the GCGC. According to recommendation G.10, the variable remuneration amounts granted to the Board of Management member should be invested primarily in shares of the company or granted on a share-based basis. The remuneration system approved by the Annual General Meeting on 11 May 2021 stipulates that both the non-performance-related (fixed) remuneration components and the performance-related (variable) remuneration components of the members of the Board of Management of Biotest AG are not share-based, but are paid out in cash. In the opinion of the Supervisory Board, the existing system of long-term remuneration has proven itself, so there has been no reason to make structural changes to date.
- Biotest AG did not follow recommendation G.12 of the GCGC. In the event of the termination of a service contract of a member of the Board of Management, the payment of outstanding variable remuneration components attributable to the period up to the termination of the contract should be made in accordance with recommendation G.12 of the GCGC and according to the originally agreed targets and comparison parameters and due dates or holding periods specified in the contract. The current service contracts of the members of the Board of Management do not contain any explicit provisions in this regard. As the current provisions are considered appropriate in the event of the departure of a member of

the Board of Management, the Supervisory Board is of the opinion that there is still no need to include a corresponding provision in the service contracts of the members of the Board of Management.

Biotest AG further declares to comply with the recommendations of the German Corporate Governance Code in the version dated 28 April 2022, with the exception of the aforementioned deviations. The Declaration of Compliance has been published on the Company's website (https://www.biotest.com/de/de/investor_relations.cfm#).

Dreieich, 5 March 2025

For the Board of Management



Peter Janssen

For the Supervisory Board



Dr. Bernhard Ehmer

In addition to this latest version, earlier versions of the Declaration of Compliance can also be viewed on and downloaded from the Biotest website.

The report on the remuneration of the Board of Management and the Supervisory Board is publicly available on the website of Biotest AG (at https://www.biotest.com/de/de/investor_relations.cfm#).